Will Ashworth

Will Ashworth

InvestorPlace Contributor

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

Alphabet Could Learn Something From Its Failed Moonshot

By Will Ashworth, InvestorPlace Contributor

Alphabet's so-call "Other Bets" may never be big contributors to the fortunes of GOOG stock. But that's not a reason to stop taking the moon shots.

Nio Stock’s Newest Backers Are Betting On Chinese Success

By Will Ashworth, InvestorPlace Contributor

Nio recently secured $1 billion in funding, but Nio stock has gone sideways ever since. Should shareholders be concerned?

Does Disney’s $11 Billion in Debt Make It a Buy or Sell?

By Will Ashworth, InvestorPlace Contributor

Disney (NYSE:DIS) raised $11 billion in new debt. Does that make DIS stock a buy or a sell given the current economic environment?

In This Economy, General Electric Is NOT a Buy

By Will Ashworth, InvestorPlace Contributor

General Electric reports Q1 2020 results on April 29. With Baker Hughes (NYSE:BKR) announcing it will book a $15 billion impairment in the first quarter against its Oilfield Services and Oilfield Equipment operating units due to uncertainty surrounding the demand for oil during the pandemic.

3 Numbers to Study Before Jumping on the Tilray Bandwagon

By Will Ashworth, InvestorPlace Contributor

Before you decide to buy or sell Tilray stock and move on to another cannabis play, at least take the time to consider three numbers from its quarterly report. I won’t say which way I’m leaning toward Tilray until the end -- the last time I wrote about TLRY in November, I cautioned investors to wait for a catalyst before buying -- but I can say that Tilray’s business isn’t nearly as bad as the headlines suggest. 

Load More